BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALVEY (talquetamab) is a bispecific antibody (BSAB) that engages both CD3 on T cells and GPRC5D on tumor cells to redirect immune activity against hematologic malignancies. It is administered by injection and represents a novel mechanism for cellular immunotherapy. The drug targets patients with relapsed or refractory multiple myeloma and other B-cell malignancies.
Growth
Recent approval positions TALVEY in a high-growth phase with active field team expansion and commercial infrastructure buildout.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
Started Sep 2026
50 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
Started Aug 2026
35 enrolled
Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Started Dec 2025
25 enrolled
Relapsed Refractory Multiple Myeloma (RRMM)
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Started Dec 2025
150 enrolled
Multiple Myeloma (MM)
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Started Nov 2025
23 enrolled
Multiple Myeloma in Relapse
Worked on TALVEY at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.